Fig 1.
Evolution of Primary Analyses and Sensitivity Analyses Cohorts.
ICD, international classification of disease code; nAMD, neovascular age-related macular degeneration; VEGF, vascular endothelial growth factor.
Table 1.
Patient Demographics and Baseline Characteristics Among Patients Receiving Ranibizumab or Aflibercept for the Management of nAMD.
Fig 2.
Annual Mean Number of Injections and Annual Mean Number of Non-injection Visits in the First Year of Therapy in Patients Receiving Treatment with Ranibizumab or Aflibercept for the Management of nAMD.
Results are not adjusted for bilateral treatment. **p < 0.0001. nAMD, neovascular age-related macular degeneration.
Fig 3.
Dose Distribution of Index Medication Among Patients Receiving Ranibizumab and Aflibercept For Management of nAMD During 1-Year Follow-Up.
nAMD, neovascular age-related macular degeneration.
Table 2.
Number of Injections and Physician Visits Per Year.
Table 3.
Dosing Intervals Between Intravitreal Injections.
Fig 4.
Annual Mean Number of Injections With any Anti-VEGF Treatment and Annual Mean Number of Non-injection Visits in The First Year of Therapy in Patients Starting Treatment with Ranibizumab or Aflibercept for Management of nAMD.
Results are not adjusted for bilateral treatment and include patients who may have changed to another anti-VEGF treatment during the 1-year follow-up period. **p < 0.0001. nAMD, neovascular age-related macular degeneration; VEGF, vascular endothelial growth factor.